MoonLake Immunotherapeutics (MLTX NASDAQ) stock market data APIs
$47.3519
0.85(1.8%)
as of June 30, 2025
Try our APIs with
free plan!
MoonLake Immunotherapeutics Financial Data Overview
Price chart is built with
Anychart
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Prev. Close
47.3519
Open
48.1986
High
48.521
Low
47.0952
52 wk Range
31.4201-58.26
Market Cap
3 016 M
Shares Outstanding
63 474 K
EPS
-0.63
Beta
1.23
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MoonLake Immunotherapeutics data using free add-ons & libraries
Get MoonLake Immunotherapeutics Fundamental Data
MoonLake Immunotherapeutics Fundamental data includes:
- Net Revenue:
- EBITDA: -169 321 360
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.7355
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MoonLake Immunotherapeutics News
New
Bullish Two Hundred Day Moving Average Cross - MLTX
In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) crossed above their 200 day moving average of $49.17, changing hands as high as $49.73 per share. MoonLake Immunotherapeuti...
MoonLake Immunotherapeutics' SWOT analysis: nanobody firm's stock poised for pivotal phase III data
MoonLake Immunotherapeutics (NASDAQ:MLTX), a biopharmaceutical company specializing in dermatology and rheumatology treatments, is approaching a critical juncture in its development. The firm, which l...
Notable healthcare headlines for the week: Bristol Myers Squibb, Novo Nordisk and Sanofi in focus
Wall Street's major averages took home gains on Friday, with the S&P 500 reclaiming the 6,000 level for the first time since late February, as sentiment was boosted by a strong May jobs report. Week-...
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in acquiring t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
